What is Wave Life Sciences's market cap?

Wave Life Sciences (WVE) has a market capitalization of $715.9M and trades on NASDAQ.

Who are Wave Life Sciences's competitors?

Wave Life Sciences's key competitors include Dyne Therapeutics, Inc. Common Stock, Beam Therapeutics Inc. Common Stock, Sarepta Therapeutics, and others. These companies compete in similar markets and product categories.

Who does Wave Life Sciences partner with?

Wave Life Sciences's notable partners include Novo Nordisk, Eli Lilly, Sarepta Therapeutics, and others.

Where is Wave Life Sciences headquartered?

Wave Life Sciences is headquartered in Singapore and employs approximately 268 people. It has been publicly traded since 2015.

Wave Life Sciences (WVE) Stock Fundamentals & Financials

Wave Life Sciences is a clinical-stage biotechnology company specializing in the development of RNA-based medicines through its proprietary PRISM platform.

Market cap

$715.94M-44.1%

Net income-$210.5M—

Free cash flow-$208.4M-5.2%

EPS (diluted)-$1.06—

Trailing twelve months · change vs. prior year

Earnings

Q3 2026 report

October 27, 2026

Revenue$13.2MBeat by $8.6M EPS-$0.30Beat by $0.03

Read the full report

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full

Revenue$13.2M—

Operating income-$66.0M-17.2%

Net income-$61.9M-15.0%

EPS (diluted)-$0.30+6.3%

Balance sheet

See full

Cash & equivalents$197.3M+0.6%

Total debt$43.3M+119%

Total equity$401.9M+223%

Total assets$507.9M+110%

Cash flow

See full

Operating cash flow-$60.1M-34.6%

CapEx$15.0K-94.0%

Free cash flow-$60.2M-33.9%

Valuation & ratios

Valuation

See full

Market cap$715.94M-44.1%

Enterprise value$561.9M-50.9%

Returns & leverage

See full

Return on equity-80%—

Debt / equity0.1×-0.1×

Current ratio8.4×+5.9×

Competitors

By market cap

ALN

Alnylam Pharmaceuticals$23.3B-60.5%

Madrigal Pharmaceuticals, Inc.$10.0B+4.7%

Ionis Pharmaceuticals$7.4B-38.6%

Dyne Therapeutics, Inc.$3.2B-5.0%

Beam Therapeutics$3.0B+23.7%

Sarepta Therapeutics, Inc.$2.0B-16.5%

Wave Life Sciences$715.9M-45.8%

Korro Bio, Inc.$209.1M-38.9%

By revenue growth

Beam Therapeutics+159%

Madrigal Pharmaceuticals, Inc.+149%

ALN

Alnylam Pharmaceuticals+56.2%

Ionis Pharmaceuticals-7.4%

By net margin

ALN

Alnylam Pharmaceuticals52.85%+50.3pp

Sarepta Therapeutics, Inc.-6.93%—

Madrigal Pharmaceuticals, Inc.-25.32%+29.4pp

Ionis Pharmaceuticals-64.66%-36.2pp

Wave Life Sciences-66.5%—

Beam Therapeutics-742.45%—

Profile

Wave Life Sciences is a clinical-stage biotechnology company specializing in the development of RNA-based medicines through its proprietary PRISM platform. The company utilizes multiple modalities, including RNA interference, RNA editing, and antisense splicing, to target the transcriptome and treat both rare and common genetic disorders. Their approach focuses on optimizing oligonucleotide chemistry to enhance drug potency and durability without the need for complex delivery vehicles.

Competitive position

A pioneer in stereopure oligonucleotide chemistry and RNA editing, holding a leading position in endogenous ADAR-mediated RNA correction.

GeographiesUnited States, Europe, Global

Customer segmentsPatients, Healthcare providers

Business modelR&D intensive, Biopharmaceutical drug development

SuppliersRaw material suppliers for oligonucleotide synthesis, Specialized contract manufacturing organizations, Clinical research organizations

CustomersSpecialty pharmacies, Hospitals, Government healthcare payers, Private insurance companies

CountrySingapore

Listed2015

Employees268.0

CEOPaul Bolno

SectorHealthcare

IndustryBiotechnology

Websitewavelifesciences.com

FilingsSEC EDGAR

FAQ

What is Wave Life Sciences's market cap?: Wave Life Sciences (WVE) has a market capitalization of $715.9M and trades on NASDAQ.
Who are Wave Life Sciences's competitors?: Wave Life Sciences's key competitors include Dyne Therapeutics, Inc. Common Stock, Beam Therapeutics Inc. Common Stock, Sarepta Therapeutics, and others. These companies compete in similar markets and product categories.
Who does Wave Life Sciences partner with?: Wave Life Sciences's notable partners include Novo Nordisk, Eli Lilly, Sarepta Therapeutics, and others.
Where is Wave Life Sciences headquartered?: Wave Life Sciences is headquartered in Singapore and employs approximately 268 people. It has been publicly traded since 2015.